Scalper1 News
Specialty-drug giant Valeant Pharmaceuticals (VRX) said Wednesday that it had appointed an interim CEO while its regular CEO continues to recover from pneumonia. Valeant said that it had tapped Howard Schiller, a board member who served as CFO from 2011 until last June, to lead the company during J. Michael Pearson’s indefinite leave of absence. Word that Pearson had been hospitalized first emerged on Christmas Day, and the following Monday Scalper1 News
Scalper1 News